Sugi Predict

Sugi Predict / Compounds / SCHEMBL1333807

SCHEMBL1333807

SCHEMBL1333807

CC(=O)SC1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.50
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ EPHX1 P07099 1/20 0.43
▸ HPGD P15428 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ RECQL P46063 1/20 0.40
▸ DDB1 Q16531 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ NAMPT P43490 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ RORC P51449 1/20 0.38
▸ GPR119 Q8TDV5 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31309157 0.87 NR1H2 (0.47) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL57238 0.86 HPGD (0.48) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL1335071 0.86 HPGD (0.48) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL56416 0.86 HPGD (0.48) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL20636196 0.86 NR1H2 (0.47) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL1068167 0.84 MEN1 (0.54) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL1068169 0.84 MEN1 (0.54) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL1068166 0.84 MEN1 (0.54) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL21640265 0.82 NR1H2 (0.54) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL56417 0.82 HPGD (0.54) USP2SMN1; SMN2EPHX1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US disclosed
US-20250276967-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES SIGNAL PHARMACEUTICALS, LLC 2025-09-04 — — US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP disclosed
US-12338235-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CELGENE CORPORATION (US) 2025-06-24 — — US disclosed
CN-119894878-A Aromatic amide derivative and preparation method and application thereof 浙江海正药业股份有限公司 2025-04-25 — — CN disclosed
US-20250115591-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2025-04-10 — — US disclosed
US-11981667-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2024-05-14 — — US disclosed
WO-2024078569-A1 AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 浙江海正药业股份有限公司 2024-04-18 — — WO disclosed
WO-2024061371-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 广州威诺森医药科技有限公司 2024-03-28 — — WO disclosed
CN-111132974-B Sulfonamide carboxamide compounds 英夫拉索姆有限公司 2023-11-21 — — CN disclosed
CN-102153553-A Oral administration carbapenem compound containing amino sulfonamide-azetidine SHANDONG XUANZHU PHARMACEUTICAL CO LTD OWN 2011-08-17 — — CN disclosed
WO-2010084767-A1 N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY RAQUALIA PHARMA INC. (JP) 2010-07-29 — — WO disclosed
WO-2010084767-A1 N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY RAQUALIA PHARMA INC. (JP) 2010-07-29 — — WO disclosed
US-6306880-B1 HETEROCYCLIC ALCOHOL DERIVATIVES AS FUNGICIDES SANKYO COMPANY, LIMITED (JP) 2001-10-23 — — US disclosed
US-20010031768-A1 Triazole antifungal agent SANKYO COMPANY LIMITED (JP) 2001-10-18 — — US disclosed
US-20010031778-A1 Triazole antifungal agent SANKYO COMPANY LIMITED (JP) 2001-10-18 — — US disclosed
US-6300357-B1 FOR THERAPY OF MYCOTIC DISEASE OF A HUMAN BEING AND AN ANIMAL SANKYO COMPANY, LIMITED (JP) 2001-10-09 — — US disclosed
EP-0841327-B1 TRIAZOLE ANTIFUNGAL AGENT SANKYO CO (JP) 2001-10-04 — — EP disclosed
US-5977152-A Triazole antifungal agent SANKYO COMPANY, LIMITED (JP) 1999-11-02 — — US disclosed
EP-0841327-A1 TRIAZOLE ANTIFUNGAL AGENT SANKYO COMPANY LIMITED (JP) 1998-05-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276967-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CYP8B1, HAX1, HRH4 NR1H2 170/4885USP2 2484/4885SMN1; SMN2 668/4885
US-20010031768-A1 Triazole antifungal agent ERG28, RIF1, NAT1 NR1H2 976/4885USP2 3652/4885SMN1; SMN2 4693/4885
US-12338235-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CYP8B1, HAX1, HRH4 NR1H2 170/4885USP2 2484/4885SMN1; SMN2 668/4885
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 NR1H2 152/4885USP2 1571/4885SMN1; SMN2 3395/4885
US-11981667-B2 Sulfonamide carboxamide compounds NLRP3, NOD1, PYCARD NR1H2 437/4885USP2 2788/4885SMN1; SMN2 2759/4885
US-20250115591-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 NR1H2 403/4885USP2 2264/4885SMN1; SMN2 2436/4885
US-20010031778-A1 Triazole antifungal agent ERG28, NAT1, RIF1 NR1H2 943/4885USP2 4168/4885SMN1; SMN2 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.